The German Severe Asthma Registry

German Asthma Net e.V.

S. Korn[1], M. Hübner[1], K.Ch. Bergmann[2], A. Jahn[3], P. Kardos[4], A. Koch[5], M. Lommatzsch[6], E. Hamelmann[7], R. Buhl[1]

[1] Pulmonary Department, Mainz University Hospital, [2] Allergy-Centre-Charité, Charité – Universitätsmedizin Berlin, [3] Institute of Medical Biostatistics, Epidemiology, and Informatics, Mainz University Hospital, [4] Lungenpraxis Maingau, Frankfurt, [5] Medical Clinic III for Pneumology, Allergology and Sleep Medicine, University Hospital Bergmannsheil, Bochum, [6] Department for Respiratory and Critical Care Medicine, Rostock University Hospital, [7] Children's Hospital of Ruhr University, Bochum, GERMANY

German Asthma Net

- Severe persistent asthma represents the highest unmet medical need among the asthmatic population
- Improvement of the understanding of severe disease progresses in pediatric and adult asthma

German Asthma Net

- Registry to optimise diagnostic evaluation and treatment of adults and children with severe asthma
- Detailed characterization of patients with severe asthma



www.german-asthma-net.de

Severe Asthma Registry

Definition of severe asthma (adults)

Either high-intensity treatment (with or without asthma control) (A) or moderate-intensity treatment and poor asthma control (B):

A. High-intensity treatment
- Maintenance therapy with high dose ICS (≥ 1000µg BDP equivalent) + LABA and/or LTRA and/or theophylline
- Maintenance therapy with OCS ≥ past 3 months
- Omalizumab therapy

B. Moderate-intensity treatment
- Maintenance therapy with moderate to high dose ICS (≥ 500µg BDP equivalent) + LABA and/or LTRA and/or theophylline

and poor asthma control
- Daytime asthma symptoms ≥ 3x/week
- Limitations of activities due to asthma
- Nocturnal asthma symptoms
- Exacerbation(s) ≥1 in the past year requiring ≥ 3 days OCS treatment
- Impaired lung function: FEV1 < 80% pred.

German Severe Asthma Registry

261 patients as of August 2012

Analysis of patients (n=226) included by abstract authors

Parameter	Adults (n=202)	Children (n=24)
Age (yrs.)	49.4±0.9	11.8±0.9
Male	76 (38%)	11 (46%)
Never smokers	120 (59%)	24 (100%)
FEV1 (L)	1.9±0.1	2.5±0.3
FEV1 (% pred.)	61.6±1.4	86.2±4.8
eNO (ppb)	50±5	41±14
Asthma control (uncontrolled)	158 (78%)	7 (29%)
ACQ-5	2.9±0.1	1.9±0.4
AQLQ	3.9±0.1	4.8±0.3
Allergic asthma	111 (55%)	23 (96%)
Oral corticosteroids Dose (mg prednisolone)	86 (43%) 16±2	2 (8%) NA
Omalizumab Median dose (mg)	80 (40%) 300	16 (67%) 600
Exacerbations (no/year)	3.4±0.3	3.7±0.9

Categorical variables: n (%), continuous endpoints: mean ± SEM

1. Registration of patients



2. Data entry

- Medical history
- Lung function
- Asthma control and quality of life
- Comorbidities
- Symptoms
- Treatment
- Allergology

3. Data export and analysis



Summary

- Ongoing recruitment of a large number of patients with severe asthma → characterization of clinical, physiologic, cellular and biochemical parameters related to severe disease in a longitudinal assessment
- Identification of parameters that may improve diagnosis, phenotyping, management and treatment
- Ideal patient cohort to perform clinical trials
- Confirmation and extention of results of similar databases such as U-BIOPRED and SARP